Boehringer cancelled agreement with Hanmi because of competing drug’s excellence

It was pointed out Boehringer Ingelheim decided to cancel the technology introduction agreement of ‘olmutinib’ with Hanmi Pharm because of its side effects and excellent results of other competing drugs.

Hyundai Securities indicated Boehringer Ingelheim suspended development of olmutinib because of △the excellent clinical trial result of its competing drug Tagrisso and △olmutinib’s side effect...